Browsing Tag
Orna Therapeutics
5 posts
Lilly (LLY) acquires Engage Biologics for up to $202m to advance non-viral DNA delivery platform
Eli Lilly (NYSE: LLY) acquires Engage Biologics for up to $202 million, adding the Tethosome non-viral DNA platform to its genetic medicines portfolio. Read more.
Why a tiny cancer biotech suddenly looks worth more than $2bn to Eli Lilly
Eli Lilly is reportedly nearing a $2 billion-plus Kelonia deal. Read what it could mean for Lilly’s cancer pipeline, CAR-T economics, and LLY stock.
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Orna Therapeutics acquires ReNAgade Therapeutics, appoints new CEO to lead RNA therapeutics innovation
Orna Therapeutics, a pioneer in the field of circular RNA therapeutics, has officially announced its acquisition of ReNAgade…